California voters have authorized an $8.4 billion biomedical-research bond, according to unofficial returns from the November 3 election. The result is not yet final: county officials must complete their canvass by December 3, and the California secretary of state is scheduled to certify the statewide results on December 11.
That distinction matters. Proposition 38 has received political authorization, not scientific validation. It gives California permission to borrow for immunology and immunotherapy research. It does not establish that the research will produce a treatment, that the state has chosen the best institutional structure, or that future discoveries will repay the debt.
The measure will authorize up to $8.4 billion in general-obligation bonds. The Legislative Analyst’s Office analysis estimates that repayment will cost roughly $500 million to $600 million annually for about 20 years, with payments coming from the state General Fund. Some revenue from discoveries may eventually offset part of that cost, but the timing and amount are uncertain.
The science is credible. The forecast is not guaranteed.
There is no serious scientific dispute that immunology and immunotherapy are important fields. The immune system is already central to cancer treatment, vaccine development and research into infectious, cardiovascular and neurological disease. Cellular therapies and immune-targeting drugs have demonstrated that manipulating immune responses can produce clinically meaningful results.
But the fact that a research field is productive does not mean that every large investment will be productive. Biomedical research proceeds through stages: basic discovery, applied work, clinical testing, regulatory review and, eventually, patient use. Most projects do not pass through all of them. A bond can finance laboratories, investigators, data, clinical infrastructure and early experiments. It cannot purchase a successful clinical trial.
That is the first distinction California will need to preserve. The scientific opportunity is real. The promised medical and financial returns remain projections.
A research system designed by ballot
Proposition 38 creates two principal funding channels. About half of the bond proceeds would go to a qualifying nonprofit research institute selected by the California Department of Public Health. The other half would be distributed through competitive grants overseen by an Advisory and Accountability Research Council.
The structure is unusually specific. The measure requires at least $4.2 billion to support research involving cancer, heart disease and Alzheimer’s disease. It also limits administrative spending, requires public reporting and independent financial audits, directs recipients to seek revenue from funded discoveries and generally requires treatments developed through the research to be sold in California at a 20 percent discount.
Those provisions sound like accountability. Some are. But accountability is not merely the presence of an audit or a discount requirement. It also requires independent review, transparent decision-making, reliable outcome measures and a public record capable of showing what happened when projects failed.
The institute criteria appear to fit the California Institute for Immunology and Immunotherapy, a UCLA-affiliated organization connected to the initiative’s principal backer, medical-device inventor Gary K. Michelson. That does not prove the institute is unqualified. It does mean California should explain, in public and before substantial funds are released, how it will evaluate the institute’s staffing, governance, financial controls, scientific leadership and capacity to manage billions of dollars.
A young institution can produce important science. Many successful research organizations began with limited staff and ambitious plans. The relevant question is not whether the institute is new. It is whether the state has created a sufficiently rigorous process for determining when an institution is ready to receive public money on this scale.
Competitive grants are not automatically independent grants
The second funding channel raises a different concern. Proposition 38 describes the grants as competitive, but the council that awards them is built around representatives of California universities and nonprofit research institutions. The council will set priorities and select recipients from eligible institutions represented within its structure.
That arrangement may provide expertise and institutional continuity. It may also create conflicts that must be managed rather than assumed away. Who selects the reviewers? How are conflicts involving a university, the institute, UCLA or Mr. Michelson disclosed and handled? Will reviewers see negative results, failed applications and replication problems? Can researchers outside the most powerful institutions compete on equal terms?
These are not procedural details. They determine whether the program functions as a scientific funding system or as a politically defined distribution network.
The measure’s supporters are right that federal research funding can be unstable and that states may reasonably seek to protect scientific capacity. But independence from Washington does not automatically produce independence from institutional influence. California will still need peer review, conflict-of-interest rules and public reporting strong enough to distinguish research quality from political endorsement.
California has tried voter-funded biomedical research before
Proposition 38 also belongs to a longer California experiment. Voters approved Proposition 71 in 2004 and Proposition 14 in 2020, authorizing a combined $8.5 billion for stem-cell and regenerative-medicine research. The California Institute for Regenerative Medicine has since supported laboratories, training programs, companies and clinical development.
The California Institute for Regenerative Medicine’s annual reports describe substantial clinical infrastructure, including hundreds of clinical trials and thousands of participants across its clinical network. Those are meaningful outputs. They are not the same as demonstrating that the bonds produced approved therapies or generated financial returns greater than the state’s costs.
That history complicates the argument on both sides. Supporters can point to California’s ability to build durable research institutions outside the ordinary federal appropriations process. Critics can ask how long biomedical development takes, how success should be measured and whether a new initiative has learned from the governance problems of the earlier one.
The useful comparison is not “California funded stem cells, therefore this measure will succeed.” It is: what did California learn about peer review, intellectual property, patient access, conflicts of interest, failed projects and long-term evaluation before creating another bond-funded research system?
The debt arrives before the treatment
Proposition 38 requires a share of revenue from funded discoveries to go first toward repaying the state. That provision may eventually return money to the General Fund. It does not remove the state’s obligation to repay the bonds if discoveries do not generate substantial licensing or royalty income.
The financial risk is therefore straightforward even when the scientific outcome is not. Californians will begin carrying the debt-service obligation while the research proceeds through years of experiments, clinical trials and regulatory decisions. The state may receive valuable knowledge without receiving a profitable product. That would still be a legitimate public outcome, but it would not be the same as financial self-sufficiency.
Nor does the promised 20 percent patient discount answer the access question by itself. California will need to define which treatments qualify, how the discount is calculated, whether it applies to all patients or products, and how compliance will be monitored. A discount on an expensive therapy may be meaningful. It may also remain inaccessible to patients who lack coverage, transportation, specialist care or a diagnosis made early enough for treatment to help.
What the public should be able to see
The strongest test of Proposition 38 will not be the number of grants announced or the prestige of the scientists involved. It will be the quality of the public record.
California should publish the institute-selection criteria and decision, funding agreements, staffing plans, audited financial statements, grant-review procedures, conflict disclosures, milestone reports, licensing agreements and patient-access data. It should report negative results and terminated projects, not only discoveries that support the program’s original promises. It should explain how the new system interacts with the National Institutes of Health, the University of California, private biotechnology companies and existing CIRM programs.
Most importantly, the state should distinguish among outputs that are often treated as interchangeable: money awarded, experiments completed, findings independently replicated, clinical trials advanced, treatments approved and patients helped.
California has not purchased cures. It has authorized a long, expensive experiment in how a democracy funds science.
The experiment may produce valuable research and durable institutions. It may also expose the limits of using ballot language to design a technically complex funding system. Its success will be established over time by whether California can show which questions it funded, which findings survived independent testing, which projects failed, what patients received and who remained accountable when promising biology did not become a treatment.
